Remus Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kzzhmtngnqusm45i6wd8v51s.pdf

Key Takeaways


The Two-Speed Margin Structure

Anjali Shah: "we are looking at a better percentage in future with at least moving ahead to what is 5% now. I think we can move ahead to 8-10% is something that we are eyeing. But eventually we will see how the operations add up and at what period they add up."

B2C: The Growth and Margin Pivot


Geographic Expansion: Emerging Markets Plus the US Base

Arpit Shah: "unless and until I personally or someone from my team personally don't visit the country, we don't start working on that."

Africa: A Deliberately Narrow, High-Margin Play

Arpit Shah: "you said why we are not picking 80% of the market. I think my shareholders will be happy that I am picking something which is 20% but getting better PAT levels on that."

Product Portfolio and Capabilities


Guidance & Commitments

CommitmentSpecificsTimeline
B2C revenue shareReach 18–20% of total revenue (from 13% currently)Before end of FY26
B2C revenue shareReach 25% of total revenueNext 1.5 years
PAT marginImprove from 5% to 8–10%1–2 years, depending on operational factors
Clinical trials subsidiaryOperational and adding to marginsH2 FY26
Emerging market revenue shareGrow from ~20% to 25–30% of total revenueNo fixed date; both US and emerging businesses to grow at recent pace
New country entriesKenya (40 products registering), Chile, Dominican Republic, AlgeriaUnderway; gated by management due diligence visits

Key Metrics

MetricQ2 FY26
Revenue₹400 cr, +47% YoY
Operational EBITDA₹27 cr, +28% YoY
EBITDA margin6.75%
PAT after minority interest₹17.5 cr, +34% YoY
PAT margin5%, management targeting 8–10% going forward
B2C revenue share13% of total revenue, up from 4% in prior-year H1
B2B revenue share87% of total revenue
B2C revenue share target18–20% by end of FY26, 25% in next 1.5 years
B2B segment EBITDA margin32–33% (Remus standalone and Bolivian/Guatemalan subsidiary)
B2C segment EBITDA margin35%+
US subsidiary revenue share~80% of consolidated revenue
US subsidiary standalone revenue growth~40% (H1 FY26 vs H1 FY25)
New product approvals secured37 during the period
National tender submissionsOver 20 products per market
Countries with product reachMore than 40